Venetoclax Shows Promise Among Previously Treated Patients With Waldenström Macroglobulinemia
Researchers sought to determine whether venetoclax would be safe and effective in patients with previously treated Waldenström macroglobulinemia.
Waldenstrom Macroglobulinemia
Ibrutinib May Reduce Risk of Bleeding Events in Acquired von Willebrand Syndrome Secondary to Waldenström Macroglobulinemia
Researchers described a case study that suggested ibrutinib may have beneficial effects in patients with acquired von Willebrand syndrome that is secondary to Waldenström macroglobulinemia.
Fixed-Duration Chemo-Free Treatment Efficacious in Patients With Relapsed/Refractory Waldenström Macroglobulinemia
Researchers sought to determine whether fixed-duration chemotherapy-free treatment with obinutuzumab and idelalisib would be effective in patients with R/R WM.
FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
Waldenström Macroglobulinemia 2020 Year-End Update: Diagnosis and Treatment Considerations
A year-end update on WM, a distinct entity of lymphoplasmacytic lymphoma presenting with monoclonal pleomorphic immunoglobulin M (IgM) proteins, was recently published in the American Journal of Hematology.
Case Report Details COVID-19 Reinfection in Immunocompromised Patient
A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.
Ibrutinib Effectiveness in Symptomatic, Previously Treated Waldenström Macroglobulinemia
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow Up
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
Improving Survival in Younger Patients With Waldenström Macroglobulinemia
Researchers evaluated data from younger patients with Waldenström macroglobulinemia to determine features that predict outcomes in this patient population.
Long-Term Zanubrutinib Treatment Effective for Majority of Patients With Waldenström Macroglobulinemia
The overall response rate was 95.9%, with 100% of patients in the TN group and 93.9% of patients in the RR group responding.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...